Logo

The US FDA Approves New Indication and Formulation for Astellas' Myrbetriq

Share this

The US FDA Approves New Indication and Formulation for Astellas' Myrbetriq

Shots:

  • The FDA has approved Myrbetriq (ER tablets) for NDO in children aged ≥3yrs. who weigh ≥35kg and Myrbetriq Granules (ER oral suspension) for NDO in pe children aged 3yrs. The FDA has granted pediatric exclusivity for Myrbetriq- resulting in an additional 6mos. period of market exclusivity
  • The approval for the NDO indication is based on P-III study involves assessing Myrbetriq in children & adolescents aged 3-<18yrs with NDO using clean intermittent catheterization
  • Myrbetriq tablets are available in the US while Myrbetriq granules are developed for use in younger children- or children with NDO who have difficulty in swallowing tablets and will be available in the US at the end of 2021

  Ref: PRNewswire | Image: Astellas

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions